![]() ![]() Overall, apixaban users had higher ischemic cerebrovascular event rates (HR 1.86 95% CI 1.00–3.45) and lower bleeding rates (HR 0.66 95% CI 0.49–0.88), but outcome rates varied by dosing alignment. However, ischemic cerebrovascular event rates were higher among dabigatran and rivaroxaban users that received reduced dosages without an indication. ![]() Clinical outcome rates were similar for dabigatran and rivaroxaban users versus warfarin users. Median age (84 years), CHA 2DS 2-Vasc (5), and ATRIA risk scores (3) were similar across medications. Subgroup analyses were performed by alignment of DOAC dosing with labeling. Absolute rate differences (RD) and cause-specific hazard ratios (HR) with 95% confidence intervals (CI) were estimated. Outcomes included ischemic stroke or transient ischemic attack (i.e., ischemic cerebrovascular event), bleeding (extracranial or intracranial), other vascular events, death, and a composite of all outcomes. Initiators of DOACs (2881 apixaban, 1289 dabigatran, 3735 rivaroxaban) were 1:1 propensity matched to warfarin initiators. US nursing home residents aged > 65 years with non-valvular atrial fibrillation enrolled in fee-for-service Medicare for > 6 months. To compare the safety and effectiveness of DOACs versus warfarin. Research comparing direct-acting oral anticoagulants (DOACs) to warfarin has excluded nursing home residents, a vulnerable and high-risk population. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |